Cody B. Jackson

Cody B. Jackson

Auto-generated profile, based on publicly available information

Cody B. Jackson

Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2021 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
PDF file
CJCody B. Jackson
Cody B. Jackson
MFMichael Farzan
Michael Farzan
BCBing Chen
Bing Chen
HCHyeryun Choe
Hyeryun Choe

26 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
LZLizhou Zhang
Lizhou Zhang
CJCody B. Jackson
Cody B. Jackson
HMHuihui Mou
Huihui Mou
AOAmrita Ojha
Amrita Ojha
HPHaiyong Peng
Haiyong Peng
HCHyeryun Choe
Hyeryun Choe
SARS-CoV-2 variants with spike (S)-protein D614G mutations now predominate globally. We therefore compare the properties of the mutated S protein (SG614) with the original (SD614). We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than those with SD614. This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion. Similar results are obtained with virus-like particles produced with SARS-CoV-2 M, N, E, and S proteins. However, D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may increase infectivity by assembling more functional S protein into the virion.

11 October 2023 in npj Vaccines
Verified
Journal Article
Open access
PDF file
LZLizhou Zhang
Lizhou Zhang
KMKunal R. More
Kunal R. More
AOAmrita Ojha
Amrita Ojha
CJCody B. Jackson
Cody B. Jackson
BQBrian D. Quinlan
Brian D. Quinlan
HCHyeryun Choe
Hyeryun Choe
During the COVID-19 pandemic, Pfizer-BioNTech and Moderna successfully developed nucleoside-modified mRNA lipid nanoparticle (LNP) vaccines. SARS-CoV-2 spike protein expressed by those vaccines are identical in amino acid sequence, but several key components are distinct. Here, we compared the effect of ionizable lipids, untranslated regions (UTRs), and nucleotide composition of the two vaccines, focusing on mRNA delivery, antibody generation, and long-term stability. We found that the ionizable lipid, SM-102, in Moderna’s vaccine performs better than ALC-0315 in Pfizer-BioNTech’s vaccine for intramuscular delivery of mRNA and antibody production in mice and long-term stability at 4 °C. Moreover, Pfizer-BioNTech’s 5′ UTR and Moderna’s 3′ UTR outperform their counterparts in their contribution to transgene expression in mice. We further found that varying N1-methylpseudouridine content at the wobble position of mRNA has little effect on vaccine efficacy. These findings may contribute to the further improvement of nucleoside-modified mRNA-LNP vaccines and therapeutics.

1 December 2017 in Immunity
Verified
Journal Article
Closed access
WCWei Cao
Wei Cao
HKHisako Kayama
Hisako Kayama
MCMei Lan Chen
Mei Lan Chen
ADAmber Delmas
Amber Delmas
ASAmy Sun
Amy Sun
MSMark S. Sundrud
Mark S. Sundrud

1 January 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
CJCody B. Jackson
Cody B. Jackson
LZLizhou Zhang
Lizhou Zhang
MFMichael Farzan
Michael Farzan
HCHyeryun Choe
Hyeryun Choe

27 August 2019 in mBio
Verified
Journal Article
Open access
PDF file
BSByoung-Shik Shim
Byoung-Shik Shim
YKYoung-Chan Kwon
Young-Chan Kwon
MRMichael J. Ricciardi
Michael J. Ricciardi
MSMars Stone
Mars Stone
YOYuka Otsuka
Yuka Otsuka
HCHyeryun Choe
Hyeryun Choe
Preexisting immunity against dengue virus or West Nile virus was previously reported to mediate antibody-dependent enhancement (ADE) of Zika virus (ZIKV) infection in a mouse model. We show here that ZIKV-immune plasma samples from both symptomatic and asymptomatic individuals mediated ZIKV ADE of infection in vitro and in mice. In a lethal infection model with a viral inoculum 10 times higher, both ADE and protection were observed, depending on the amount of infused immune plasma. In a vertical-transmission model, ZIKV-immune plasma infused to timed pregnant mice increased fetal demise and decreased the body weight of surviving fetuses. Depletion of IgG from an immune plasma abolished ADE of infection, and the presence of purified IgG alone mediated ADE of infection. Higher viral loads and proinflammatory cytokines were detected in mice treated with ZIKV-immune plasma samples compared to those receiving control plasma. Together, these data show that passive immunization with homotypic ZIKV antibodies, depending on the concentration, could either worsen or limit a subsequent ZIKV infection. IMPORTANCE Antibody-dependent enhancement (ADE) of virus infection is common to many viruses and is problematic when plasma antibody levels decline to subneutralizing concentrations. ADE of infection is especially important among flaviviruses, many of which are the cause of global health problems. Recently, human plasma samples immune to heterologous flaviviruses were shown to promote Zika virus (ZIKV) infection. Here we showed in immunocompromised mouse models that homologous immune plasma samples protect mice from subsequent infection at high antibody concentrations but that they mediate ADE of infection and increase ZIKV pathogenesis in adult mice and fetal demise during pregnancy at low concentrations.